| Business Summary | | Vasogen
Inc.
is
engaged
in
the
development
and
commercialization
of
a
therapeutic
platform
technology
designed
to
harness
the
human
immune
response
to
treat
disease.
Vasogen's
lead
clinical
program,
now
entering
late-stage
development,
focuses
on
applying
the
Company's
proprietary
immune
modulation
therapy
to
the
treatment
of
peripheral
arterial
disease.
Vasogen's
immune
modulation
therapy
is
also
in
clinical
development
for
a
number
of
other
indications
characterized
by
immune
system
dysfunction,
including
psoriasis,
congestive
heart
failure,
ischemia/reperfusion
injury,
chronic
lymphocytic
leukemia,
and
graft-versus-host
disease.
Through
collaborations
with
leading
international
researchers,
Vasogen
is
also
advancing
the
development
of
therapeutic
interventions
for
the
treatment
of
additional
autoimmune
diseases
and
neurological
disorders. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Vasogen
Inc.
develops
and
commercializes
therapies
for
immune
system
modulation
for
the
treatment
of
cardiovascular,
autoimmune
and
other
cell-mediated
inflammatory
conditions.
For
the
six
months
ended
5/31/01,
the
company
reported
no
revenues.
Net
loss
before
US
GAAP
rose
42%
to
C$6.8
million.
Higher
loss
reflects
an
increase
in
professional
fees,
general
and
administrative
and
research
and
development
expenses. | More
from
Market Guide: Significant
Developments |
| Officers | | | FY2000 Pay | |
| William Grant Chairman | -- | David Elsley Pres,
CEO | $290K | William Cochrane Vice
Chairman | -- | Christopher Waddick Vice-Pres,
Fin., CFO, Corp. Sec. and Treasurer | 209K | Eldon Smith Vice-Pres, Scientific Affairs | 138K | Dollar
amounts are as of 30-Nov-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|